New crystallized lithium aims to improve bipolar treatment
NCT ID NCT07540338
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a new crystallized lithium (AL001) to standard lithium carbonate in 20 people with bipolar I disorder. Participants take each drug for 14 days and undergo MRIs and blood tests to measure how lithium enters the brain and body. The goal is to see if AL001 is safer and works better at reaching the brain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AL001 (crystallized lithium) and lithium carbonate
What this could lead to
If successful, AL001 could offer a safer or more effective way to manage bipolar I disorder by delivering lithium more efficiently to the brain.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply broadly. Lithium can cause side effects like kidney or thyroid issues, and the new form may not prove better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••